BioSpace

Over the last year, the reaction to generative AI has changed - and so have behaviors. People are integrating AI to become more productive and it is happening now in healthcare and life sciences. Hear from senior leaders at Microsoft and IQVIA to get their take on how generative AI is impacting productivity, employee engagement and how to mitigate risks. Host ⁠⁠⁠Lori Ellis⁠⁠⁠, Head of Insights, BioSpace Guests Matt O’Donnell, Industry Executive Health & Life Sciences, Microsoft ⁠⁠Mike King⁠⁠⁠, Senior Director of Product and Strategy, IQVIA

The weight loss market sees more ups and downs - Altimmune joins the fray and sees a stock jump while Pfizer experiences setbacks; and European Medicines Agency seeks additional information as part of its ongoing review of the potential risk of suicide and self-harm thoughts associated with the class. Meanwhile, AbbVie buys ImmunoGen for a cool $10B and scores a win with Teliso-V as ADC momentum continues to build. Plus, the FDA investigates malignacies linked to CAR-T. BioSpace's Lori Ellis, Greg Slabodkin and Tyler Patchen discuss.

Patient behavior has always had an influence on clinical trials - so how do we contend with missing and/or irregular data now that it is feeding AI models? And how do providers continue to work with patients to optimize and grow data pools? This is the third and final part of a discussion focused upon data bias, accuracy, access and the future of AI in drug development. Host ⁠⁠Lori Ellis⁠⁠, Head of Insights, BioSpace Guests ⁠⁠Paul Agapow⁠⁠, Director of Innovation, Data Science and Strategy, GlaxoSmithKline⁠⁠⁠ ⁠Mike King⁠⁠, Senior Director of Product and Strategy, IQVIA ⁠⁠Nindhana Paranthaman⁠⁠, Executive Medical Director, Exelixis ⁠⁠Moritz von Stosch⁠⁠, Chief Information Officer, DataHow

The breadth of AI in healthcare applications is broad. How much human oversight is necessary or preferred when leveraging AI in the interest of patient safety? Listen to this in-depth discussion on how AI can help identify end-to-end data weaknesses, as well as broader implications regarding the inevitability of human interaction. This is part two of a discussion focused upon data bias, accuracy, access and the future of AI in drug development. Host ⁠Lori Ellis⁠, Head of Insights, BioSpace Guests ⁠Paul Agapow⁠, Director of Innovation, Data Science and Strategy, GlaxoSmithKline⁠ Mike King⁠, Senior Director of Product and Strategy, IQVIA ⁠Nindhana Paranthaman⁠, Executive Medical Director, Exelixis ⁠Moritz von Stosch⁠, Chief Information Officer, DataHow

This week we talk struggles with GLP-1 drug shortages and what that might mean for Novo/Lilly competitors; Regeneron and Sanofi positive results for ⁠⁠Dupixent⁠⁠ in COPD. Plus, Merck buys Caraway, Beigene's deal with Ensem, ups and downs for Flagship. Join BioSpace's Lori Ellis, Greg Slabodkin and Tyler Patchen as they discuss the most important biopharma news this week.

Last Thursday, the U.K.’s Medicines and Healthcare products Regulatory Agency (MHRA) approved CRISPR/Cas9 gene-edited therapy exagamglogene autotemcel (exa-cel). Will the FDA follow suit? What can patients expect the price tag to be? Plus, a good handful of approvals for AstraZeneca, Pfizer and Astellas' Xtandi, and Keytruda. Join BioSpace's Lori Ellis, Greg Slabodkin and Heather McKenzie as they discuss the news this week.

This is part one of a discussion focused upon data bias, accuracy, access and the future of AI in drug development. Topics explored are ROI, human bias, data challenges, data management plans, and human expertise. Host Lori Ellis, Head of Insights, BioSpace Guests Paul Agapow, Director of Innovation, Data Science and Strategy, GlaxoSmithKlineMike King, Senior Director of Product and Strategy, IQVIA Nindhana Paranthaman, Executive Medical Director, Exelixis Moritz von Stosch, Chief Information Officer, DataHow

Last week, the FDA approved Eli Lilly's obesity drug Zepbound, creating an anticipated intense competition between it and Novo Nordisk's Wegovy. BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the weight loss race and the future of this drug class. Plus, a quick recap on Valneva, the FDA's first Chikungunya vaccine approval.

This week (our inaugural episode!) BioSpace's Greg Slabodkin, Tyler Patchen and Lori Ellis discuss the good, the bad and the ugly of biopharma's reported Q3 earnings. They also tackle what's going on at Pfizer, ADCs, deals and more. Want to dive deeper on BioSpace? Read more on Pfizer's recent cuts⁠ as part of their cost-savings program and more insight on Q3 earnings for Gilead, ⁠⁠Novo Nordisk,⁠⁠ ⁠⁠Moderna⁠⁠, ⁠⁠Vertex⁠⁠, ⁠⁠BMS⁠⁠, ⁠⁠Lilly,⁠⁠ ⁠⁠GSK⁠⁠. Meanwhile, industry-wide ⁠layoffs⁠ march on and in case you missed it - bankruptcies reached a record high.